PharmTech News

Articles

Probiodrug has signed an agreement with Rentschler Biotechnologie GmbH for the development of PBD-C06, a pGlu-Abeta-specific monoclonal antibody, as treatment for patients with Alzheimer’s disease.

Probiodrug Signs Manufacturing Agreement with Rentschler for Monoclonal Antibody PBD-C06

The new facility will house the company’s expanding R&D operations.

Adaptimmune to Open New R&D Facility in Oxfordshire, UK

Randi Hernandez was science editor at Pharmaceutical Technology from September 2014 to May 2017.

The results from an international study on nivolumumab, published in the New England Journal of Medicine, suggest a paradigm shift in the standard of care for previously treated lung cancer patients.

New Study Reveals Immunotherapy More Effective Than Chemotherapy

Roche says its trial results validate the hypothesis that B lymphocytes are key targets in the mediation of the inflammatory damage characteristic of multiple sclerosis.

Roche's Ocrelizumab Reduces MS Progression in Phase III Trials

MedImmune and 3M Drug Delivery Systems collaborate to develop toll-like receptor (TLR) agonists for immuno-oncology.

MedImmune and 3M Collaborate on TLR Agonist Cancer Therapies

Intuniv (guanfacine hydrochloride prolonged-release tablets) is the first selective alpha-2A adrenergic receptor agonist licensed for the treatment of attention deficit hyperactivity disorder in Europe.

Shire’s Once-Daily ADHD Tablets Approved in Europe

The fully humanized monoclonal antibody is licensed to Bristol-Myers Squibb.

Innate Pharma Expects Data on Lirilumab by 2016

Nexvet Biopharma, a veterinary biologics developer, secured a dedicated, cGMP biologics manufacturing facility in Tullamore, Ireland, and plans to invest in disposable technology.

Nexvet Secures Biomanufacturing Facility for Veterinary Biologics

Abenza acquired biopharmaceutical CDMO PacificGMP and expanded the company’s San Diego facility.

Abenza Acquires US CDMO PacificGMP

According to AstraZeneca, the purchase of the biologics bulk plant will double the company's biologics manufacturing capacity in the US.

Bio/Pharma News